Aytu BioPharma, Inc. (AYTU)

NASDAQ: AYTU · IEX Real-Time Price · USD
0.188
-0.005 (-2.34%)
At close: Sep 23, 2022 4:00 PM
0.190
+0.002 (1.225%)
After-hours: Sep 23, 2022 7:57 PM EDT
-2.34%
Market Cap 11.72M
Revenue (ttm) 92.70M
Net Income (ttm) -111.47M
Shares Out 62.43M
EPS (ttm) -4.24
PE Ratio n/a
Forward PE 10.70
Dividend n/a
Ex-Dividend Date n/a
Volume 646,193
Open 0.190
Previous Close 0.192
Day's Range 0.183 - 0.196
52-Week Range 0.180 - 3.290
Beta -0.27
Analysts Buy
Price Target 5.61 (+2,888.8%)
Earnings Date Sep 27, 2022

About AYTU

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine... [Read more...]

Industry Pharmaceuticals
Employees 175
Stock Exchange NASDAQ
Ticker Symbol AYTU
Full Company Profile

Financial Performance

In 2021, Aytu BioPharma's revenue was $65.63 million, an increase of 137.52% compared to the previous year's $27.63 million. Losses were -$58.29 million, 327.9% more than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for AYTU stock is "Buy." The 12-month stock price forecast is 5.61, which is an increase of 2,888.81% from the latest price.

Price Target
$5.61
(2,888.81% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Aytu BioPharma to Report Fourth Quarter and Fiscal 2022 Financial Results on September 27, 2022

ENGLEWOOD, CO / ACCESSWIRE / September 20, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, with a development pipeline addressing rare,...

4 days ago - Accesswire

Aytu BioPharma Announces Addition of Fourth Patent License for AR101/Enzastaurin

This Fourth Patent for AR101/Enzastaurin Strengthens and Broadens the Intellectual Property Portfolio Surrounding the Treatment of Inherited Vascular Disorders Including Vascular Ehlers-Danlos Syndrome ...

1 week ago - Accesswire

Aytu BioPharma to Participate in September 2022 Investor Conferences

ENGLEWOOD, CO / ACCESSWIRE / August 24, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, with a development pipeline addressing rare, pe...

1 month ago - Accesswire

Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin

First Issued U.S. Patent Covers Methods of Treating a Broad Range of Inherited Aortic Aneurism and Related Conditions Including Vascular Ehlers-Danlos Syndrome Multiple Patent Families Filed in Key Glob...

1 month ago - Accesswire

Aytu BioPharma Announces Closing of $10.0 Million Registered Public Offering

ENGLEWOOD, CO / ACCESSWIRE / August 15, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today ...

1 month ago - Accesswire

Aytu BioPharma Announces Pricing of Public Offering

ENGLEWOOD, CO / ACCESSWIRE / August 9, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today a...

1 month ago - Accesswire

Aytu BioPharma Announces Launch of Public Offering

ENGLEWOOD, CO / ACCESSWIRE / August 8, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today a...

1 month ago - Accesswire

Aytu BioPharma to Participate in the Canaccord Genuity 42nd Annual Growth Conference

ENGLEWOOD, CO / ACCESSWIRE / July 26, 2022 / Aytu BioPharma, Inc. (the "Company") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced th...

1 month ago - Accesswire

Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of Directors

ENGLEWOOD, CO / ACCESSWIRE / June 29, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the appointment of...

2 months ago - Accesswire

Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference

ENGLEWOOD, CO / ACCESSWIRE / June 13, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the company w...

3 months ago - Accesswire

Aytu BioPharma Reports Third Quarter 2022 Financial Results and Outlines Key Strategic Priorities

Quarterly Net Revenue Increased 79% Year-Over-Year to $24.2 Million, the Highest Revenue in Company History Strategic Priorities Focused on Driving Revenue Growth, Increasing Financial Efficiencies and ...

4 months ago - Accesswire

Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Hea...

Preclinical Proof-of-Concept Study Demonstrates Effectiveness of Healight in Delaying Time to Development of Ventilator-Associated Pneumonia ENGLEWOOD, CO / ACCESSWIRE / April 25, 2022 / Aytu BioPharma,...

4 months ago - Accesswire

Aytu BioPharma Announces FDA Orange Book Listing of Newly Issued Patent for Cotempla XR-ODT(R)

ENGLEWOOD, CO / ACCESSWIRE / March 23, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that its newly is...

6 months ago - Accesswire

Aytu BioPharma to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit

ENGLEWOOD, CO / ACCESSWIRE / March 22, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that management w...

6 months ago - Accesswire

Aytu BioPharma to Participate in the 34th Annual Roth Conference

ENGLEWOOD, CO / ACCESSWIRE / March 8, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that Mark Oki, chi...

6 months ago - Accesswire

Aytu BioPharma Announces Closing of $7.6 Million Registered Offering

ENGLEWOOD, CO / ACCESSWIRE / March 7, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the closing of its...

6 months ago - Accesswire

Aytu BioPharma Announces Pricing of $7.6 Million Registered Offering

ENGLEWOOD, CO / ACCESSWIRE / March 2, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the placement to a...

6 months ago - Accesswire

Has Aytu BioPharma Inc. (AYTU) Outpaced Other Medical Stocks This Year?

Here is how Aytu BioPharma Inc. (AYTU) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.

7 months ago - Zacks Investment Research

Aytu BioPharma Announces Business and Pipeline Progress and Reports Second Quarter 2022 Financial Results

Quarterly Net Revenue Increased 53% Year-over-year to $23.1 Million PREVEnt Pivotal Study for AR101 in Vascular Ehlers-Danlos Syndrome On-track to Begin in Mid-2022 Initiation of Randomized, Sham-contro...

7 months ago - Accesswire

Aytu BioPharma Completes $15 Million Debt Refinancing

ENGLEWOOD, CO / ACCESSWIRE / January 31, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that it has ent...

7 months ago - Accesswire

Aytu BioPharma Appoints Mark Oki as Chief Financial Officer

ENGLEWOOD, CO / ACCESSWIRE / January 4, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announce...

8 months ago - Accesswire

Aytu BioPharma to Present at H.C. Wainwright BioConnect Conference

ENGLEWOOD, CO / ACCESSWIRE / January 3, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announce...

8 months ago - Accesswire

Aytu BioPharma's (AYTU) AR101 Gets FDA's Orphan Drug Status

The FDA bestows an Orphan Drug designation to Aytu BioPharma's (AYTU) AR101 for the treatment of vascular Ehlers-Danlos Syndrome.

9 months ago - Zacks Investment Research

Aytu BioPharma Announces Issuance of First U.S. Patent Supporting Healight Ultraviolet-A Respiratory Catheter

ENGLEWOOD, CO / ACCESSWIRE / November 23, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, an...

10 months ago - Accesswire

Aytu BioPharma Ranked Number 178 Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 50(TM)

ENGLEWOOD, CO / ACCESSWIRE / November 17, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, to...

10 months ago - Accesswire